Filing summary
Source mismatch: The request identifies Lisata Therapeutics, Inc. and 2016 Q3, but the supplied filing is Caladrius Biosciences, Inc.’s Form 10-Q for the quarter ended September 30, 2017. This summary reflects the supplied filing; confirm the intended issuer and period.
Business context and reporting period
Caladrius develops cellular therapies. Its lead program was CLBS03, a Phase 2 regulatory T-cell therapy for adolescents with recent-onset type 1 diabetes. The company also pursued CD34-cell programs, including a planned Japanese trial for critical limb ischemia. The statements are unaudited and cover Q3 and the nine months ended September 30, 2017.
Caladrius sold its remaining 80.1% interest in PCT to Hitachi on May 18, 2017. The sale was treated as discontinued operations, so continuing-operations results principally reflect the remaining therapeutics business.
Financial highlights
| Metric | Q3 2017 | Nine months 2017 | Comparison |
|---|---|---|---|
| Continuing revenue | No revenue reported | No revenue reported | — |
| Operating expenses | $6.13 million | $20.27 million | Q3 +7%; nine months −16% versus 2016 |
| Operating loss | $6.13 million | $20.27 million | Prior-year losses were $5.73 million and $24.01 million |
| Net loss from continuing operations | $3.55 million | $12.21 million | Prior-year losses were $6.09 million and $25.59 million |
| Net income (loss), including discontinued operations | ($3.55 million) | $25.12 million | Nine-month 2017 result included $37.33 million income from discontinued operations, principally the PCT sale |
Q3 research and development expense was $3.19 million and general and administrative expense was $2.94 million. Nine-month R&D expense declined 17% year over year, while G&A declined 14%. There is no meaningful reported gross margin for continuing operations because no continuing revenue was reported.
At September 30, cash, cash equivalents, restricted cash and marketable securities totaled approximately $64.5 million; working capital was approximately $54.4 million and stockholders’ equity was $53.3 million. Restricted cash included $5.0 million held in escrow in connection with the PCT sale. Nine-month continuing operating cash use was $16.3 million; continuing investing activities provided $23.2 million, largely reflecting the sale proceeds and investment purchases; continuing financing activities used $0.7 million. The Oxford long-term loan was repaid in May. The balance sheet showed no long-term debt and approximately $0.36 million of current notes payable.
The company recorded a $51.7 million gain on the PCT sale. The potential additional $5.0 million sale milestone was assigned zero fair value at closing; it depends on PCT reaching $125 million in qualifying cumulative revenue over 2017–2018. The company also reported income-tax benefits of $2.4 million for Q3 and $8.3 million for the nine-month period.
Changes, outlook and risks
- The PCT divestiture drove the nine-month reported net income; continuing operations remained loss-making. PCT contributed $37.3 million of discontinued-operations income in the nine-month period, including the sale gain.
- Management said cash on hand was expected to fund CLBS03 development and other operating expenses for at least 12 months from the financial-statement issuance date. It also noted that continued funding could require equity or debt issuance, partnerships, collaborations, grants or asset sales, with no assurance financing would be available on acceptable terms.
- The company expected a CLBS03 interim analysis after approximately half of trial patients reached six-month follow-up, with results anticipated in mid-to-late Q1 2018. The filing cited a satisfactory safety review based on the first 19 enrolled patients.
- CIRM awarded up to $12.2 million for the T-Rex Study; $5.7 million had been received, subject to milestones and eligible costs. A $1.9 million NIH grant for a CD34-cell study was announced October 2, 2017, after the quarter ended.
- Risks include clinical, regulatory and enrollment uncertainty; capital needs; reliance on grants and strategic partners; and potential claims against the $5.0 million PCT-sale escrow. The company also disclosed transaction and retention costs of approximately $6.9 million, including retention payments with a remaining portion payable in 2018.
Important facts to verify
- Confirm whether the intended filing is Caladrius Biosciences’ 2017 Q3 10-Q rather than the issuer and period specified in the request.
- Review the basis for management’s stated 12-month funding outlook against continuing cash use and planned clinical-development spending.
- Track CLBS03 enrollment, interim-analysis timing and results, and the conditions and remaining availability of CIRM funding.
- Check the status of the PCT escrow, any indemnification claims, and whether the contingent milestone becomes achievable.
- Distinguish continuing-business performance from the one-time PCT sale gain when assessing reported net income.